Pfizer closes Baxter vaccine acquisition; Bavarian Nordic Ebola booster tests begin in the U.K.;

> Pfizer ($PFE) has closed its deal for Baxter's ($BAX) marketed vaccines portfolio. Release

> The first clinical trials of a Bavarian Nordic's Ebola vaccine booster, which may improve the effects of a vaccine from GlaxoSmithKline ($GSK), have begun at the U.K.'s Oxford University. Report

> The U.S. has approved GlaxoSmithKline's purchase of the bulk of Novartis' ($NVS) vaccine business. Report

> This year's flu vaccine is not as effective against the current strain of the influenza virus because the virus has mutated, the CDC says. Report

> Novavax ($NVAX) has won FDA fast-track designation for its RSV F vaccine. Release

And Finally... UC Berkeley students are working on a portable chip that healthcare providers can access without the Internet to view patient vaccination records, a tool that could make it easier to provide vaccines to children in developing countries. More

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.